scholarly journals POTENTIAL IMPLICATIONS OF ASPREE ON ASPIRIN PRIMARY PREVENTION GUIDELINES

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S633-S634
Author(s):  
Anne M Murray
Keyword(s):  
Primary Prevention ◽  
Physical Disability ◽  
Low Dose ◽  
Free Survival ◽  
Healthy Elderly ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Secondary Endpoints ◽  
Prevention Guidelines

Abstract The 2016 USPSTF guidelines for aspirin to prevent CVD and colorectal cancer noted insufficient evidence to assess the balance of benefit and harm in those 70 and older. The long-awaited ASPREE trial, conducted in healthy elderly aged 70 and older (65 for US minorities), evaluated aspirin’s effect on disability-free survival, a composite of death, dementia, or persistent physical disability. CVD and cancer were pre-specified secondary endpoints, positioning ASPREE’s results to substantially inform the evidence gap noted in the USPSTF guidelines. Low-dose aspirin over 5 years did not lower CVD events or colorectal risk, but significantly increased bleeding. The ASPREE-XT observational follow-up study over the next 5-7 years will observe for potential legacy effects of aspirin on the primary and secondary outcomes of ASPREE, thus adding further evidence to define the risk-benefit profile of aspirin for primary prevention in healthy elderly.

scholarly journals RATIONALE FOR ASPREE DISABILITY-FREE SURVIVAL PRIMARY OUTCOME AND OVERVIEW OF PRIMARY OUTCOME RESULTS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S633-S633
Author(s):  
John McNeil
Keyword(s):  
Physical Disability ◽  
Primary Outcome ◽  
Low Dose ◽  
Primary Outcome Measure ◽  
Negative Effects ◽  
Vascular Events ◽  
Free Survival ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Preventive Drug

Abstract Disability-free survival (DFS), defined as survival free of disability and dementia was the primary outcome measure of the ASPREE clinical trial. As previously reported, there was no benefit of low dose aspirin on the primary end point of dementia, physical disability or death, but bleeding risks were increased. In total, 1,835 participants reached the primary endpoint, confirmed amongst approximately 3,000 who had triggered for one of the end-points. Dementia was the most labor intensive component of DFS. Several previous primary prevention aspirin studies had identified a reduction of vascular events counterbalanced by an increase in serious bleeding, leaving the question of net outcome to an intuitive decision. DFS was chosen because it balances the positive and negative effects of a preventive drug such as aspirin. It also encapsulates the primary purpose of a preventive drug in older people i.e., to prolong a healthy lifespan rather than prevent a defined disease.

scholarly journals Effect of Low-Dose Aspirin on Primary Prevention of Cardiovascular Events in Japanese Diabetic Patients at High Risk

2013 ◽  
Vol 77 (12) ◽  
pp. 3023-3028 ◽  
Author(s):  
Sadanori Okada ◽  
Takeshi Morimoto ◽  
Hisao Ogawa ◽  
Mio Sakuma ◽  
Hirofumi Soejima ◽  
...  
Keyword(s):  
Primary Prevention ◽  
High Risk ◽  
Cardiovascular Events ◽  
Low Dose ◽  
Diabetic Patients ◽  
Dose Aspirin ◽  
Low Dose Aspirin

A Practical Approach to Low-Dose Aspirin for Primary Prevention

JAMA ◽  
2019 ◽  
Vol 322 (4) ◽  
pp. 301 ◽  
Author(s):  
Kim F. Chiang ◽  
Shreya J. Shah ◽  
Randall S. Stafford
Keyword(s):  
Primary Prevention ◽  
Low Dose ◽  
Practical Approach ◽  
Dose Aspirin ◽  
Low Dose Aspirin
Sign in / Sign up

Export Citation Format

Share Document